Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Revenue of Merus N.V. (MRUS)
Revenue in 2023 (TTM): $43.95 M
According to Merus N.V.'s latest financial reports the company's current revenue (TTM) is $43.95 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Merus N.V.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $43.95 M | $-83,461,016 | $-149,207,000 | $-151,747,000 | $-154,939,000 |
| 2022 | $41.59 M | $29.6 M | $-148,259,426 | $-130,235,000 | $-131,194,000 |
| 2021 | $49.11 M | $-37,160,098 | $-77,748,192 | $-66,577,000 | $-66,816,000 |
| 2020 | $29.94 M | $-27,391,744 | $-60,931,672 | $-85,010,000 | $-85,513,000 |
| 2019 | $31.13 M | $-18,505,720 | $-49,673,488 | $-54,957,000 | $-55,151,000 |
| 2018 | $35.97 M | $35.75 M | $-39,270,898 | $-27,354,152 | $-27,761,382 |
| 2017 | $14.88 M | $14.88 M | $-50,611,848 | $-87,386,328 | $-87,685,054 |
| 2016 | $2.86 M | $1.4 M | $-29,010,138 | $-49,669,766 | $-49,669,766 |
| 2015 | $1.44 M | $1.44 M | $-24,922,922 | $-25,347,124 | $-25,347,124 |
| 2014 | $944.84 K | $-17,662,581 | $-20,814,485 | $-21,169,561 | $-21,169,561 |
| 2013 | $260.98 K | $-9,885,664 | $-13,241,183 | $-13,681,681 | $-13,681,681 |